The Greener Side of Bio
AZBio Board Chair and Co-Founder of Algae Biosciences, Glen Galster , moderates this panel discussion on the state of Arizona's green bio industry amd whwere it's going with Leif P. Christoffersen , Director of Biomass Integration, Yulex Corporation . Leif is responsible for advancing Yulex’s energy, efficiency and biomass initiatives. Prior to Yulex, Christoffersen played a key role in establishing the E.O. Wilson Biodiversity Foundation (EOWBF) with whom he maintains an active advisory role. He also spent over five years at the Diversa Corporation (Verenium Corporation and BP Biofuels), where he managed bioprospecting collaborations, as well as managed Diversa’s grants program, coordinated their scientific advisory board, and supported their international business development efforts. Christoffersen has also served as a climate change adviser to the Executive Director of UNEP at COP1 and COP2 of the Climate Change Convention (UNFCCC). At the start of his career, he worked with subsistence farmers in Costa Rica and Kenya to support and promote agroforestry practices, which included setting up exportation of organic produce. Christoffersen holds a degree from Hobart College (BA, Economics) and the University of California, San Diego (MBA, Rady School of Management). Ben Cloud , President and CEO, Phyco Biosciences, Inc ., brings over 30 years of experience as a farmer and farmland developer with operations in Arizona and Southern California. His significant experience in production agriculture including drip-micro irrigation systems and design, cropping systems, processing and marketing have contributed to the development of the Phyco production platform and business approach (To learn more, click here .) and Josh Hottenstein of the Cleantech Open
Company Presentation: NuvOx
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.
Senestech: Humane Pest Control
Senestech is a platform biotechnology company specializing in reproductive physiology. Our mission: Senestech aims to provide for the more humane treatment of animals, to improve the quality of human life, and to enhance environmental stewardship through global application of our animal fertility control technology. We are currently applying our revolutionary technology to the control of rats and mice in both agricultural and urban settings.
Tying it all together for start up success
Alan Nelson is heading the Predictive Health Analytics Initiative that aims to change the paradigm in healthcare from treating late stage disease to early diagnosis and preventive therapies that are cost-effective. He served as the Executive Director of the Biodesign Institute at ASU and holds professorships in Bioengineering and physics. He is the founder and CEO of three companies, the most recent being VisionGate, the innovator of the LuCED lung cancer early detection test. VisionGate was awarded the start-up of the year award at the recent Governors’ celebration of innovation. Alan has a PhD in Biophysics from Berkeley, holds 66 issued patents, and has published over 100 scholarly papers in biomedical imaging.
Industrial Biotech in Arizona
Where is Industrial Biotech in Arizona Today? Glen Galster, co-founder of Algae Biosciences and AZBio Chairman of the Board moderates this panel discussion from the AZBio Expo 2012 featuring: Leif P. Christoffersen, Director of Biomass Integration, Yulex Corporation . Ben Cloud, President and CEO, Phyco Biosciences, Inc ., Josh Hottenstein, Cleantech Open
MSDx: Company Presentation
MSDx, Inc .provides novel biomarker tools for studying disease processes. The company is focused on commercializing both Research Use Only (RUO) and In VitroDiagnostic (IVD) blood test products that will be used in monitoring neurological, autoimmune, and inflammatory disorders.
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.
Ground Broken for University of Arizona Cancer Center in Phoenix
Ground Broken for University of Arizona Cancer Center in Phoenix Ground was officially broken on the new University of Arizona Cancer Center (UACC) at St. Joseph's Hospital and Medical Center/Dignity Health outpatient facility in downtown Phoenix in February, 2013. Located on the Phoenix Biomedical Campus at 625 N. Sixth St., on the northwest corner of Fillmore and Seventh streets, the center is expected to be open in 2015. Follow the project's construction progress at www.phoenixcancercenter.org